Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-treatment With [177Lu]Lu-PSMA in mCRPC
NCT06866938Phase 2Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hospices Civils de Lyon. Started Apr 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06866938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866938.